Research Analysts Set Expectations for Genelux FY2024 Earnings

Genelux Co. (NASDAQ:GNLX) – Research analysts at Brookline Capital Management issued their FY2024 earnings per share estimates for shares of Genelux in a note issued to investors on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver expects that the company will earn ($0.89) per share for the year. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q4 2024 earnings at ($0.20) EPS and FY2025 earnings at ($0.70) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Genelux in a research report on Tuesday. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $18.25.

Genelux Price Performance

GNLX stock opened at $3.03 on Friday. Genelux has a 1-year low of $1.60 and a 1-year high of $6.50. The business has a 50-day moving average price of $4.05 and a 200 day moving average price of $3.09. The company has a market capitalization of $104.65 million, a P/E ratio of -3.19 and a beta of -1.41.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GNLX. Marshall Wace LLP grew its stake in shares of Genelux by 51.4% during the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock worth $368,000 after acquiring an additional 52,958 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Genelux during the fourth quarter valued at $41,000. LPL Financial LLC increased its position in shares of Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock valued at $222,000 after acquiring an additional 39,516 shares during the period. Virtu Financial LLC purchased a new stake in Genelux during the 4th quarter valued at about $25,000. Finally, LifeSteps Financial Inc. increased its holdings in shares of Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after purchasing an additional 8,715 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.